Which has higher earnings and valuation, BNTX or ARGX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $2.81B 8.25 -$1.29B -$5.88 N/A argenex $4.25B 12.60 $1.29B $22.46 38.31

Is BNTX or ARGX more profitable?

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% argenex 31.31% 44.37% 37.55%

Does the media favor BNTX or ARGX?

In the previous week, argenex had 6 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for argenex and 4 mentions for BioNTech. argenex's average media sentiment score of 0.93 beat BioNTech's score of 0.82 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BNTX or TAK?

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 41.15%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts clearly believe BioNTech is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.74 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to BNTX or TAK?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 4 mentions for BioNTech. BioNTech's average media sentiment score of 0.82 beat Takeda Pharmaceutical's score of 0.65 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or BNTX?

In the previous week, Revolution Medicines had 1 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Revolution Medicines and 4 mentions for BioNTech. Revolution Medicines' average media sentiment score of 1.70 beat BioNTech's score of 0.82 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or BNTX?

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 4 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.45 beat BioNTech's score of 0.82 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 16 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or ONC?

In the previous week, BeOne Medicines had 9 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for BeOne Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 0.82 beat BeOne Medicines' score of 0.51 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioNTech (BNTX) Competitors

$91.48 -0.08 (-0.09%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$90.80 -0.68 (-0.74%)

As of 07/17/2026 08:00 PM Eastern

Compare

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy BioNTech stock or one of its competitors? MarketBeat compares BioNTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNTech include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does BioNTech compare to argenex?

BioNTech (NASDAQ:BNTX) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.25	-$1.29B	-$5.88	N/A
argenex	$4.25B	12.60	$1.29B	$22.46	38.31

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, argenex has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

In the previous week, argenex had 6 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for argenex and 4 mentions for BioNTech. argenex's average media sentiment score of 0.93 beat BioNTech's score of 0.82 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech currently has a consensus price target of $129.13, indicating a potential upside of 41.15%. argenex has a consensus price target of $1,037.61, indicating a potential upside of 20.58%. Given BioNTech's higher possible upside, equities analysts clearly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats BioNTech on 14 of the 17 factors compared between the two stocks.

How does BioNTech compare to Takeda Pharmaceutical?

BioNTech (NASDAQ:BNTX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Takeda Pharmaceutical has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.25	-$1.29B	-$5.88	N/A
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	43.98

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 4 mentions for BioNTech. BioNTech's average media sentiment score of 0.82 beat Takeda Pharmaceutical's score of 0.65 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 41.15%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts clearly believe BioNTech is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Takeda Pharmaceutical has a net margin of 4.31% compared to BioNTech's net margin of -44.39%. Takeda Pharmaceutical's return on equity of 11.20% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.8%. BioNTech pays out -26.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 123.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BioNTech beats Takeda Pharmaceutical on 10 of the 19 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Revolution Medicines has higher earnings, but lower revenue than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
BioNTech	$2.81B	8.25	-$1.29B	-$5.88	N/A

Revolution Medicines currently has a consensus price target of $144.00, indicating a potential downside of 22.65%. BioNTech has a consensus price target of $129.13, indicating a potential upside of 41.15%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Revolution Medicines had 1 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Revolution Medicines and 4 mentions for BioNTech. Revolution Medicines' average media sentiment score of 1.70 beat BioNTech's score of 0.82 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

Revolution Medicines beats BioNTech on 9 of the 16 factors compared between the two stocks.

How does BioNTech compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Teva Pharmaceutical Industries has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.13	$1.41B	$1.33	24.06
BioNTech	$2.81B	8.25	-$1.29B	-$5.88	N/A

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 30.57%. BioNTech has a consensus price target of $129.13, indicating a potential upside of 41.15%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 4 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.45 beat BioNTech's score of 0.82 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	16 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BioNTech's net margin of -44.39%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

Teva Pharmaceutical Industries beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to BeOne Medicines?

BioNTech (NASDAQ:BNTX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BeOne Medicines has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.25	-$1.29B	-$5.88	N/A
BeOne Medicines	$5.74B	5.97	$286.93M	$4.47	69.80

BioNTech currently has a consensus price target of $129.13, suggesting a potential upside of 41.15%. BeOne Medicines has a consensus price target of $390.92, suggesting a potential upside of 25.29%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has a net margin of 8.94% compared to BioNTech's net margin of -44.39%. BeOne Medicines' return on equity of 12.06% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 9 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for BeOne Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 0.82 beat BeOne Medicines' score of 0.51 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats BioNTech on 10 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.13B	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-15.56	21.03	27.25	23.92
Price / Sales	8.25	167.40	515.05	89.60
Price / Cash	68.52	154.08	52.99	60.41
Price / Book	0.95	8.26	10.69	6.18
Net Income	-$1.29B	$23.83M	$3.59B	$332.29M
7 Day Performance	-0.01%	-3.47%	-2.20%	-2.05%
1 Month Performance	0.65%	2.69%	1.63%	-2.18%
1 Year Performance	-16.85%	45.93%	25.64%	17.67%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	4.4744 of 5 stars	$91.48 -0.1%	$129.13 +41.2%	-16.9%	$23.13B	$2.81B	N/A	7,807	News Coverage Analyst Upgrade
ARGX argenex	4.6365 of 5 stars	$876.25 -0.2%	$1,037.61 +18.4%	+52.4%	$54.58B	$4.25B	39.01	1,863	News Coverage Upcoming Earnings
TAK Takeda Pharmaceutical	1.9215 of 5 stars	$16.49 -0.4%	N/A	+18.9%	$52.70B	$28.32B	42.28	47,000	News Coverage Analyst Upgrade
RVMD Revolution Medicines	1.975 of 5 stars	$183.95 -1.6%	$144.00 -21.7%	+386.1%	$39.73B	$11.58M	N/A	250	Positive News
TEVA Teva Pharmaceutical Industries	4.8101 of 5 stars	$32.15 -2.4%	$41.78 +29.9%	+99.0%	$37.89B	$17.26B	24.17	33,950	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Summary

How does BioNTech compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BioNTech compare to argenex?

Which has higher earnings and valuation, BNTX or ARGX?

Do insiders and institutionals believe in BNTX or ARGX?

Which has more volatility & risk, BNTX or ARGX?

Does the media favor BNTX or ARGX?

Do analysts recommend BNTX or ARGX?

Is BNTX or ARGX more profitable?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Which has higher valuation & earnings, BNTX or TAK?

Does the media refer more to BNTX or TAK?

Do analysts recommend BNTX or TAK?

Is BNTX or TAK more profitable?

Is BNTX or TAK a better dividend stock?

Which has more volatility & risk, BNTX or TAK?

Do institutionals & insiders have more ownership in BNTX or TAK?

Summary

How does BioNTech compare to Revolution Medicines?

Which has more risk and volatility, RVMD or BNTX?

Do institutionals and insiders believe in RVMD or BNTX?

Which has higher valuation and earnings, RVMD or BNTX?

Do analysts prefer RVMD or BNTX?

Does the media favor RVMD or BNTX?

Is RVMD or BNTX more profitable?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Which has preferable valuation and earnings, TEVA or BNTX?

Do analysts rate TEVA or BNTX?

Does the media favor TEVA or BNTX?

Do insiders and institutionals have more ownership in TEVA or BNTX?

Which has more risk and volatility, TEVA or BNTX?

Is TEVA or BNTX more profitable?

Summary

How does BioNTech compare to BeOne Medicines?

Do insiders & institutionals have more ownership in BNTX or ONC?

Which has better valuation & earnings, BNTX or ONC?

Do analysts prefer BNTX or ONC?

Is BNTX or ONC more profitable?

Does the media prefer BNTX or ONC?

Which has more risk and volatility, BNTX or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools